Nuwellis, Inc. Files 8-K Reporting "Other Event"

TL;DR

Nuwellis (NUWE) filed an 8-K for an 'Other Event' - details TBD.

AI Summary

Nuwellis, Inc. filed an 8-K on August 19, 2025, reporting an "Other Event." The filing does not contain specific details about the event itself, but it confirms the company's reporting status and corporate information. Nuwellis, Inc. was formerly known as CHF Solutions, Inc. and Sunshine Heart, Inc.

Why It Matters

This 8-K filing indicates a significant event has occurred for Nuwellis, Inc. that requires public disclosure, though the nature of the event is not detailed in this specific filing.

Risk Assessment

Risk Level: medium — The filing itself is routine, but the 'Other Event' could represent a material development requiring further investigation.

Key Numbers

• 001-35312 — SEC File Number (Identifies the company's filing history with the SEC.)
• 0001506492 — Central Index Key (Unique identifier for the filer in the SEC EDGAR system.)

Key Players & Entities

• Nuwellis, Inc. (company) — Registrant
• August 19, 2025 (date) — Date of Report
• CHF Solutions, Inc. (company) — Former Name
• Sunshine Heart, Inc. (company) — Former Name
• 12988 Valley View Road, Eden Prairie, MN 55344 (address) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share NUWE Nasdaq Capital Marke

Filing Documents

• ef20054176_8k.htm (8-K) — 28KB
• 0001140361-25-031828.txt ( ) — 152KB
• nuwe-20250819.xsd (EX-101.SCH) — 4KB
• nuwe-20250819_lab.xml (EX-101.LAB) — 21KB
• nuwe-20250819_pre.xml (EX-101.PRE) — 16KB
• ef20054176_8k_htm.xml (XML) — 4KB

01

Item 8.01. Other Events. On August 19, 2025, Nuwellis, Inc. (the " Company ") announced that it has entered into a non-binding letter of intent to acquire Rendiatech, Ltd., an Israeli-based medical device company specializing in real-time urine flow and acute kidney injury monitoring technologies. The proposed acquisition is expected to support the Company's strategy to expand its current technology platform beyond ultrafiltration by potentially adding continuous renal health monitoring technologies that provide clinicians with earlier insight into fluid status and kidney function. The parties are engaged in the due diligence process and should they agree to proceed, the transaction is anticipated to close in the fourth quarter of 2025, pending final Board approval and closing conditions.

Forward-Looking Statements

Forward-Looking Statements Certain statements in this Current Report on Form 8-K may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2025 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this Current Report on Form 8-K, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. The Company does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 19, 2025 NUWELLIS, INC. By: /s/ John L. Erb Name: John L. Erb Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR